Navigation Links
Kendle Appoints Jeffrey M. Zucker to Lead Global Patient Recruitment Efforts
Date:8/23/2010

CINCINNATI, Aug. 23 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the appointment of Jeffrey M. Zucker as Senior Director and Global Head, Patient Recruitment.  Zucker will provide global leadership for the development and implementation of innovative strategies to accelerate patient recruitment, improve retention and support the timely and efficient delivery of Phase I-IV clinical development programs for the Company's biopharmaceutical customers.  He brings nearly 15 years of clinical development and management experience to Kendle.

"Patient recruitment is at the core of the clinical development process," said Stephen Cutler, PhD, Senior Vice President and Chief Operating Officer.  "Finding the right patients for the right studies and keeping them engaged throughout is essential to producing sound clinical research.  Jeff's extensive management experience across many facets of the biopharmaceutical industry will be a great asset for our customers and we are pleased to welcome him to Kendle."

Zucker brings extensive experience from across the biopharmaceutical industry, including management positions focused on site selection and patient recruitment.  In his most recent position, he led global trial optimization efforts for Merck & Co. He also has served as Director of Inpatient Operations at CRI Worldwide and as founder and President of Applied Research Trials, a biopharmaceutical consulting firm focused on improving clinical research trials and processes.  Zucker has held leadership positions for Eli Lilly, Princeton Biomedical Research and multiple clinical investigative sites. He holds a Master of Science in Group Process and Group Psychotherapy from Hahnemann University in Philadelphia and a Bachelor of Science in psychology from Pennsylvania State University.  

Innovative patient recruitment strategies in support of investigative sites have earned Kendle consistent recognition as a CRO of choice.  The Company is the only CRO to be ranked consistently among the top three CROs to work with in the 2010, 2009, 2008 and 2007 CenterWatch surveys of U.S. and European investigative sites.  

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's website at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Rated a Top CRO to Work with for Fourth Consecutive Year
2. Kendle Announces New Revolving Credit Facility
3. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast
4. Kendle to Present at UBS Global Life Sciences Conference
5. Kendle to Present at Robert Baird 2009 Health Care Conference
6. Kendle Realigns C-Suite Leadership to Drive Increased Innovation, Productivity and Organizational Efficiency
7. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
8. Kendle Names Jarrod Pontius Chief Legal Officer
9. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
10. Kendle Announces First Quarter 2009 Results
11. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments have ... is part of the Protein and Cell Analysis Education Webinar Series , will ... technology fits in current and future applications. , Many flow cytometers have unique ...
(Date:4/19/2017)... MA (PRWEB) , ... April 19, 2017 , ... ... a $1.5M Series A-1 financing round. This event adds to several other early ... of its’ Executive and Scientific Teams. , ThermaGenix will use proceeds ...
(Date:4/19/2017)... April 19, 2017  As a Bronze ... Heroin Summit ,  Proove® Biosciences, Inc. announces ... environmental, and lifestyle factors to accurately predict prescription ... of Southern California (USC), the Interventional Pain Institute ... publish results showing that Proove Opioid Risk® accurately ...
(Date:4/18/2017)... ... April 18, 2017 , ... METTLER ... readings to concentration levels and vice-versa. , One of the key applications for ... in concentration control or monitoring. The principle of this analytical method is based ...
Breaking Biology Technology:
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
(Date:3/23/2017)... -- The report "Gesture Recognition and Touchless Sensing Market by Technology ... Forecast to 2022", published by MarketsandMarkets, the market is expected to be worth ... and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):